Moderna Exceeds Sales Expectations Amid Strategic Cost Reductions
Moderna surpassed Wall Street's sales predictions with robust COVID booster demand and strategic cost cuts. Despite a lower-than-expected quarterly loss, it adjusted its 2025 sales forecast due to shifts in UK revenue deliveries. The company aims for further cost reductions to manage declining vaccine sales.
Moderna easily outstripped Wall Street's sales expectations, reporting a smaller second-quarter loss than anticipated. This was fueled by the strong demand for its Spring COVID booster and significant cost-cutting measures.
In an updated guidance, Moderna lowered its 2025 sales forecast to a range of $1.5 billion to $2.2 billion, cutting $300 million from the top end. This adjustment comes as the company rescheduled some UK revenue deliveries to early 2026.
The Massachusetts-based vaccine manufacturer reported $142 million in quarterly revenue, marking a 41% decline from the previous year but still above the $112.9 million expected by analysts. Despite a challenging landscape, Moderna is focused on new mRNA products and achieving operational efficiencies.
(With inputs from agencies.)
Google News